Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

Robert A. Adair, Victoria Roulstone, Karen J. Scott, Ruth Morgan, Gerard J. Nuovo, Martin Fuller, Deborah Beirne, Emma J. West, Victoria A. Jennings, Ailsa Rose, Joan Kyula, Sheila Fraser, Rajiv Dave, David A. Anthoney, Alison Merrick, Robin Prestwich, Amer Aldouri, Oliver Donnelly, Hardev Pandha, Matt CoffeyPeter Selby, Richard Geoffrey Vile, Giles Toogood, Kevin Harrington, Alan A. Melcher

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune response, represent a promising approach to the treatment of cancer. However, how they evade the antiviral immune response and their selective delivery to, and replication in, tumor over normal tissue has not been investigated in humans. Here, we treated patients with a single cycle of intravenous reovirus before planned surgery to resect colorectal cancer metastases in the liver. Tracking the viral genome in the circulation showed that reovirus could be detected in plasma and blood mononuclear, granulocyte, and platelet cell compartments after infusion. Despite the presence of neutralizing antibodies before viral infusion in all patients, replication-competent reovirus that retained cytotoxicity was recovered from blood cells but not plasma, suggesting that transport by cells could protect virus for potential delivery to tumors. Analysis of surgical specimens demonstrated greater, preferential expression of reovirus protein in malignant cells compared to either tumor stroma or surrounding normal liver tissue. There was evidence of viral factories within tumor, and recovery of replicating virus from tumor (but not normal liver) was achieved in all four patients from whom fresh tissue was available. Hence, reovirus could be protected from neutralizing antibodies after systemic administration by immune cell carriage, which delivered reovirus to tumor. These findings suggest new preclinical and clinical scheduling and treatment combination strategies to enhance in vivo immune evasion and effective intravenous delivery of oncolytic viruses to patients in vivo.

Original languageEnglish (US)
Article number138ra77
JournalScience Translational Medicine
Volume4
Issue number138
DOIs
StatePublished - Jun 13 2012

Fingerprint

Oncolytic Viruses
Neoplasms
Neutralizing Antibodies
Liver
Immune Evasion
Oncogenic Viruses
Viral Genome
Granulocytes
Antiviral Agents
Colorectal Neoplasms
Blood Cells
Blood Platelets
Neoplasm Metastasis
Viruses
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adair, R. A., Roulstone, V., Scott, K. J., Morgan, R., Nuovo, G. J., Fuller, M., ... Melcher, A. A. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Science Translational Medicine, 4(138), [138ra77]. https://doi.org/10.1126/scitranslmed.3003578

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. / Adair, Robert A.; Roulstone, Victoria; Scott, Karen J.; Morgan, Ruth; Nuovo, Gerard J.; Fuller, Martin; Beirne, Deborah; West, Emma J.; Jennings, Victoria A.; Rose, Ailsa; Kyula, Joan; Fraser, Sheila; Dave, Rajiv; Anthoney, David A.; Merrick, Alison; Prestwich, Robin; Aldouri, Amer; Donnelly, Oliver; Pandha, Hardev; Coffey, Matt; Selby, Peter; Vile, Richard Geoffrey; Toogood, Giles; Harrington, Kevin; Melcher, Alan A.

In: Science Translational Medicine, Vol. 4, No. 138, 138ra77, 13.06.2012.

Research output: Contribution to journalArticle

Adair, RA, Roulstone, V, Scott, KJ, Morgan, R, Nuovo, GJ, Fuller, M, Beirne, D, West, EJ, Jennings, VA, Rose, A, Kyula, J, Fraser, S, Dave, R, Anthoney, DA, Merrick, A, Prestwich, R, Aldouri, A, Donnelly, O, Pandha, H, Coffey, M, Selby, P, Vile, RG, Toogood, G, Harrington, K & Melcher, AA 2012, 'Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients', Science Translational Medicine, vol. 4, no. 138, 138ra77. https://doi.org/10.1126/scitranslmed.3003578
Adair, Robert A. ; Roulstone, Victoria ; Scott, Karen J. ; Morgan, Ruth ; Nuovo, Gerard J. ; Fuller, Martin ; Beirne, Deborah ; West, Emma J. ; Jennings, Victoria A. ; Rose, Ailsa ; Kyula, Joan ; Fraser, Sheila ; Dave, Rajiv ; Anthoney, David A. ; Merrick, Alison ; Prestwich, Robin ; Aldouri, Amer ; Donnelly, Oliver ; Pandha, Hardev ; Coffey, Matt ; Selby, Peter ; Vile, Richard Geoffrey ; Toogood, Giles ; Harrington, Kevin ; Melcher, Alan A. / Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. In: Science Translational Medicine. 2012 ; Vol. 4, No. 138.
@article{b2c8856a076b4c8d8c7a561a5fb06c38,
title = "Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients",
abstract = "Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune response, represent a promising approach to the treatment of cancer. However, how they evade the antiviral immune response and their selective delivery to, and replication in, tumor over normal tissue has not been investigated in humans. Here, we treated patients with a single cycle of intravenous reovirus before planned surgery to resect colorectal cancer metastases in the liver. Tracking the viral genome in the circulation showed that reovirus could be detected in plasma and blood mononuclear, granulocyte, and platelet cell compartments after infusion. Despite the presence of neutralizing antibodies before viral infusion in all patients, replication-competent reovirus that retained cytotoxicity was recovered from blood cells but not plasma, suggesting that transport by cells could protect virus for potential delivery to tumors. Analysis of surgical specimens demonstrated greater, preferential expression of reovirus protein in malignant cells compared to either tumor stroma or surrounding normal liver tissue. There was evidence of viral factories within tumor, and recovery of replicating virus from tumor (but not normal liver) was achieved in all four patients from whom fresh tissue was available. Hence, reovirus could be protected from neutralizing antibodies after systemic administration by immune cell carriage, which delivered reovirus to tumor. These findings suggest new preclinical and clinical scheduling and treatment combination strategies to enhance in vivo immune evasion and effective intravenous delivery of oncolytic viruses to patients in vivo.",
author = "Adair, {Robert A.} and Victoria Roulstone and Scott, {Karen J.} and Ruth Morgan and Nuovo, {Gerard J.} and Martin Fuller and Deborah Beirne and West, {Emma J.} and Jennings, {Victoria A.} and Ailsa Rose and Joan Kyula and Sheila Fraser and Rajiv Dave and Anthoney, {David A.} and Alison Merrick and Robin Prestwich and Amer Aldouri and Oliver Donnelly and Hardev Pandha and Matt Coffey and Peter Selby and Vile, {Richard Geoffrey} and Giles Toogood and Kevin Harrington and Melcher, {Alan A.}",
year = "2012",
month = "6",
day = "13",
doi = "10.1126/scitranslmed.3003578",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "138",

}

TY - JOUR

T1 - Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

AU - Adair, Robert A.

AU - Roulstone, Victoria

AU - Scott, Karen J.

AU - Morgan, Ruth

AU - Nuovo, Gerard J.

AU - Fuller, Martin

AU - Beirne, Deborah

AU - West, Emma J.

AU - Jennings, Victoria A.

AU - Rose, Ailsa

AU - Kyula, Joan

AU - Fraser, Sheila

AU - Dave, Rajiv

AU - Anthoney, David A.

AU - Merrick, Alison

AU - Prestwich, Robin

AU - Aldouri, Amer

AU - Donnelly, Oliver

AU - Pandha, Hardev

AU - Coffey, Matt

AU - Selby, Peter

AU - Vile, Richard Geoffrey

AU - Toogood, Giles

AU - Harrington, Kevin

AU - Melcher, Alan A.

PY - 2012/6/13

Y1 - 2012/6/13

N2 - Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune response, represent a promising approach to the treatment of cancer. However, how they evade the antiviral immune response and their selective delivery to, and replication in, tumor over normal tissue has not been investigated in humans. Here, we treated patients with a single cycle of intravenous reovirus before planned surgery to resect colorectal cancer metastases in the liver. Tracking the viral genome in the circulation showed that reovirus could be detected in plasma and blood mononuclear, granulocyte, and platelet cell compartments after infusion. Despite the presence of neutralizing antibodies before viral infusion in all patients, replication-competent reovirus that retained cytotoxicity was recovered from blood cells but not plasma, suggesting that transport by cells could protect virus for potential delivery to tumors. Analysis of surgical specimens demonstrated greater, preferential expression of reovirus protein in malignant cells compared to either tumor stroma or surrounding normal liver tissue. There was evidence of viral factories within tumor, and recovery of replicating virus from tumor (but not normal liver) was achieved in all four patients from whom fresh tissue was available. Hence, reovirus could be protected from neutralizing antibodies after systemic administration by immune cell carriage, which delivered reovirus to tumor. These findings suggest new preclinical and clinical scheduling and treatment combination strategies to enhance in vivo immune evasion and effective intravenous delivery of oncolytic viruses to patients in vivo.

AB - Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune response, represent a promising approach to the treatment of cancer. However, how they evade the antiviral immune response and their selective delivery to, and replication in, tumor over normal tissue has not been investigated in humans. Here, we treated patients with a single cycle of intravenous reovirus before planned surgery to resect colorectal cancer metastases in the liver. Tracking the viral genome in the circulation showed that reovirus could be detected in plasma and blood mononuclear, granulocyte, and platelet cell compartments after infusion. Despite the presence of neutralizing antibodies before viral infusion in all patients, replication-competent reovirus that retained cytotoxicity was recovered from blood cells but not plasma, suggesting that transport by cells could protect virus for potential delivery to tumors. Analysis of surgical specimens demonstrated greater, preferential expression of reovirus protein in malignant cells compared to either tumor stroma or surrounding normal liver tissue. There was evidence of viral factories within tumor, and recovery of replicating virus from tumor (but not normal liver) was achieved in all four patients from whom fresh tissue was available. Hence, reovirus could be protected from neutralizing antibodies after systemic administration by immune cell carriage, which delivered reovirus to tumor. These findings suggest new preclinical and clinical scheduling and treatment combination strategies to enhance in vivo immune evasion and effective intravenous delivery of oncolytic viruses to patients in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84862550301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862550301&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003578

DO - 10.1126/scitranslmed.3003578

M3 - Article

C2 - 22700953

AN - SCOPUS:84862550301

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 138

M1 - 138ra77

ER -